SB4066, titled the Safeguarding Women from Chemical Abortion Act, would treat the FDA approval of mifepristone for termination of intrauterine pregnancy as if it had been withdrawn 14 days after enactment. The bill would also make it unlawful under the Federal Food, Drug, and Cosmetic Act to introduce that drug into interstate commerce for that use, and would deem mifepristone misbranded if its labeling indicates it may be used alone or with another drug to terminate an intrauterine pregnancy.
In addition to the FDA-related provisions, the bill creates a new federal tort cause of action against manufacturers of mifepristone for bodily injury or mental-health harm allegedly attributable, in whole or in part, to use of the drug. A person could sue in federal or state court for compensatory damages, punitive damages, and attorney’s fees and costs. The bill also states that it does not preempt any state law providing other remedies and does not affect federal obscenity law under 18 U.S.C. 1461.
Impact
If enacted, the bill would significantly alter federal treatment of mifepristone by effectively revoking its approval for abortion-related use and exposing manufacturers to federal enforcement consequences for interstate distribution and labeling. It would also create a nationwide private right of action that could expand litigation against drug manufacturers and potentially affect access to medication abortion across states. The bill would not directly amend state abortion laws, but it could interact with them by limiting the availability of mifepristone and by preserving any additional state remedies.
Sentiment
The available record shows the bill was introduced and referred to the Senate Committee on Health, Education, Labor, and Pensions, with no recorded votes or committee debate in the provided materials. Based on the bill’s framing and title, it is clearly intended to restrict chemical abortion and to provide remedies for alleged harms, suggesting strong support from anti-abortion advocates and likely opposition from abortion-rights supporters, medical providers, and pharmaceutical stakeholders. Because no transcripts or votes are included, there is no documented legislative sentiment beyond the bill’s introduction.
Contention
The main points of contention are the bill’s attempt to override the existing FDA approval status of mifepristone, its characterization of the drug as misbranded for abortion-related labeling, and the creation of a broad tort remedy for physical and mental-health harms. Supporters would likely argue the bill protects women and provides accountability for drug manufacturers, while opponents would likely argue it interferes with FDA authority, threatens access to medication abortion, and invites expansive litigation based on contested medical and legal claims. The bill’s preservation of state remedies may also be viewed differently: supporters may see it as allowing additional protections, while opponents may see it as compounding legal exposure.